TARA (TARA) Stock Analysis
Verdict: AVOID
Protara faces acute dilution risk with a 10.5-month cash runway before TARA-002 phase 2 data, making near-term equity raises likely.
Investment score: 33/100
The model evaluates Protara Therapeutics as an AVOID due to severe cash burn of -$56.46M annually against a cash balance of $49.66M, implying approximately 10.5 months of cash runway. Recent CEO stock sales of 215,687 shares at $4.09 and a 30.7% price drop over 90 days signal heightened equity dilution risk before commercial revenue materializes.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| AVXL | -9.28 | 1.97 | 0.00 | -4.88 | — | 0.00 |
| ELDN | -2.71 | 4.24 | 0.00 | -2.48 | — | 0.00 |
| PLX | 11.22 | 3.03 | 2.70 | 7.60 | — | 0.23 |
| ALEC | -1.76 | -21.64 | 15.54 | -1.75 | — | -8.50 |
| KROS | -2.94 | 0.82 | 23.21 | -1.26 | — | -5.54 |